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Abstract 
LifeTrack® technology enables the time-temperature stability profiles of even complex freeze-sensitive vaccines to 
be monitored in real time.  Unlike freeze-resistant vaccines, freeze-sensitive vaccines do not obey a simple 
exponential Arrhenius law degradation equation.  As a result, present vaccine stability indicators, such as Vaccine 
Vial Monitors (VVM), do not function adequately for these vaccines.  LifeTrack electronic stability tags allow even a 
complex freeze-sensitive vaccine’s fitness for use to be instantly evaluated by unsophisticated users with no 
knowledge of the vaccine, and with no special equipment.  This novel electronic tag technology takes advantage of 
advances in low-cost microprocessors, batteries, and visual displays to compare a vaccine’s real-life environmental 
history versus a sophisticated stability model, and continually determine if the vaccine’s stability remains 
acceptable.  This technology enables “at a glance” assessment of a vaccine’s suitability and remaining lifetime, and 
also allows for more detailed supplemental statistical data to be obtained in order to determine exactly how and 
when stability failures occurred.  
This ability to allow users to visually detect deteriorated freeze-sensitive vaccines, coupled with an ability to 
determine exactly where in the supply chain unwanted levels of vaccine deterioration have occurred, could 
potentially bring an entirely new level of precision to vaccine supply chain management.  The LifeTrack electronic 
stability monitoring tag may be a particularly useful tool to help address the present high rate of accidental freezing 
of freeze-sensitive vaccines in the cold chain.    
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1. Introduction 
This conference is largely focused on the early stages of vaccine development.  Although for early stage work, it 
is common to assume that the various vaccine candidates under investigation are stable, what actually happens in 
real life?   
In real life, vaccines start deteriorating the instant after they are first created.  In fact, vaccines are so delicate that 
this poses a major problem once vaccines hit the real world. For example, consider vaccines listed in the Australian 
Immunisation handbook and WHO immunization book, which are available on the web1,2.  The Australian 
document lists 19 widely used vaccines, and of these 19 vaccines, 17 out of 19 are heat sensitive, and 14 out of 19 
are also freeze sensitive.   
Now consider two different vaccines, Hepatitis A and Oral Polio Vaccine (OPV), shown in Figure 1. 
Figure 1 
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Hepatitis A vaccine is an example of a “freeze sensitive” vaccine.  The instructions say “do not freeze, discard if 
the vaccine has been exposed to temperatures of 0 oC or lower”.  Although Hepatitis A vaccine is freeze sensitive, it 
is also quite heat resistant, and it is stable for up to 15 months at 37 oC.  The reason why the Hepatitis A vaccine is 
so sensitive to freezing is that it is an alum-based vaccine.  Freezing causes the vaccine antigens to dissociate from 
the alum particles.  It turns out that most alum-based vaccines are freeze sensitive, and as we shall unfortunately see 
for our discussion, alum is very widely used in vaccines.    
By contrast, OPV is very tolerant to freezing.  The OPV vaccine can be stored for up to two years at -20 oC.
However OPV is very heat sensitive.  OPV deteriorates after about a week at room temperature, and even faster at 
higher temperatures.  Thus OPV is a very delicate vaccine from the heat standpoint, but very robust from the cold 
standpoint.   
Figure 2 
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The real problem is that vaccines must pass through the cold chain from initial production through final use.  The 
cold chain is basically a series of refrigerators and refrigerated transport systems between the manufacturer and the 
final user.  At any step of the way, if any refrigerator or transport unit isn’t storing the vaccines correctly, the 
vaccines can be damaged.  This is shown in Figure 2. 
As you can see from the figure, the cold chain can have a lot of links.  In this simplified diagram, we see how the 
vaccine travels from international transport to airports, then to a primary vaccine storehouse, then to one or more 
intermediate vaccine storehouses, then to health centers, health posts.  Moreover, each of these main cold chain 
refrigerators is connected by one or more levels of refrigerated transport in-between.   
It only takes one refrigerator set to too low a temperature to damage a freeze sensitive vaccine.  What is the 
probability of this happening?  Unfortunately, a recent PATH study by Matthias3  shows that the probability of 
accidental freezing is quite high.  This study showed that at any step of the cold chain, 14-35% of the refrigerators 
may accidentally freeze the vaccines.  The study showed that the overall chance of damage, by the time the vaccine 
passes through the average multi-link cold chain, can be as high as 75-100%.  This is a big problem, particularly 
when you realize that most of deaths caused by vaccine preventable diseases result from diseases treated by freeze 
sensitive vaccines.   
Until recently, WHO has mainly focused on the other problem, which is vaccine damage due to excess heat.  
WHO has spent much effort on this heat damage problem, and has come up with a chemical detection tag, called 
Vaccine Vial Monitors, to help detect heat damaged vaccines.  Currently, WHO mandates that Vaccine Vial 
Monitors (VVM) be put on all vaccines 4, 5.  A picture of VVM is shown in Figure 3. 
VVM are basically chemical tags with a “bull’s eye” appearance.  In the center of the VVM tag, there is a 
chemical that gradually turns darker with heat and time.  When the center color of the VVM matches the color of the 
outer rim, then the vaccine is considered no longer good to use.   
VVM were originally developed for OPV, and they are really quite good for this application.  TempTime, the 
VVM manufacturer, found that it is possible to adjust the tag chemistry to fit the exponential decay curve of OPV 
reasonably well.   
The problem, however, is that as previously discussed, many vaccines (e.g. diphtheria, tetanus, pertussis, 
hepatitis B, and others) are damaged by freezing.  Unfortunately, VVM fail to warn about this freezing damage 
problem.  VVM fail to warn about freezing because their heat detection chemical simply changes to a darker color at 
a slower rate at sub-freezing temperatures.  Thus when the vaccine and VVM dip below freezing, the VVM center 
just stays white, and users think that the vaccine is still good, even though it isn’t.   
Another unfortunate aspect of VVM is that they continue turning darker even if the vaccines are stored 
adequately.  Thus vaccines stored under proper conditions can have partially discolored VVM, suggesting to 
workers that the vaccines are not optimally fresh.  Obviously a conscientious vaccine storage manager would want 
to avoid this problem. 
Put these things together, and you can see that VVM may have the unintended consequence of encouraging 
vaccine workers to set their refrigerators at too low a temperature.  This is because the workers naturally don’t want 
the VVM indicators on their vaccines to turn darker, as this would reflect poorly on the worker’s performance.  
Rather, the workers quite naturally want to show that they are handing the vaccines properly, so they have an 
incentive to turn the refrigerator setting down.  
The problem is that in a refrigerator, there is only a few degrees difference between refrigeration and freezing.  
This is the big problem.  It only takes one worker in the chain to make this mistake, and as previously discussed, in 
fact between 15-35% of the cold chain refrigerators accidentally freeze the vaccines. 
By contrast, consider fruit.  Fruit is also transported across the world in refrigerated units in a different cold 
chain, yet 75-100% of all fruit does not arrive at the grocery having been accidentally frozen.  One reason why this 
does not happen is that frozen fruit is easy to detect by casual inspection because the fruit turns mushy. 
Well, you might be wondering, given that VVM have issues, don’t we have other ways to monitor stability?  
Unfortunately the answer here is that these other solutions don’t work very well, and thus the answer is, “not really”.   
For example, the other commonly used approach is temperature loggers.  Temperature loggers are essentially 
passive temperature recorders.  They store the temperature versus time data, but don’t attempt to analyze it.  To 
determine if the vaccine is still good, the temperature loggers must be retrieved, and the data downloaded and 
analyzed.  Unfortunately this retrieval, data downloading, and interpretation process takes both time and specialized 
equipment. This is too logistically demanding for routine use, particularly in third world situations. 
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VVM are based on a powerful concept.  This is the realization that what is needed is an ability to just glance at 
the vaccine, and immediately see if the vaccine is good or not.  This clearly is the right thing to do for vaccines, in 
principle.  
Unfortunately the reality is that the present VVM don’t match the dream – the VVM don’t detect freezing 
damage for freeze sensitive vaccines.  Even above freezing, often the VVM do not fit the actual vaccine stability 
profile all that well.  There are a huge number of vaccines, each with different stability characteristics, and WHO is 
trying to fit all of these with only four types of VVM tags.  
Figure 3 
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So the problem right now is that we don’t get prompt feedback for cold chain problems, because VVM are not 
warning about freezing, and the temperature loggers, which are just logging away without giving a warning, are too 
logistically demanding to be widely used.   
2. The LifeTrack concept 
Here I would like to propose an alternate way of monitoring vaccine stability, which I call LifeTrack technology.  
The LifeTrack device is a new type of electronic device that is a bit of a cross between a VVM and an electronic 
temperature logger 6, 7, 8, 9.   
Figure 4 
